EAGAN, Minn.--(BUSINESS WIRE)--Biothera Pharmaceuticals, Inc. today announced that Chief Executive Officer Barry Labinger will present at the Sachs Associates 2nd Annual Immuno-Oncology: BD&L and Investment Forum on Friday, June 3, 2016 at 2:30 p.m. Central Time in Chicago.
Mr. Labinger will provide an overview of Biothera and its clinical development plans in oncology, which include the initiation of three Phase 2 studies this year to evaluate the combination of company’s developmental immunotherapeutic and checkpoint inhibitors in NSCLC, metastatic melanoma and gastric cancer.
Mr. Labinger will provide an overview of Biothera and its clinical development plans in oncology, which include the initiation of three Phase 2 studies this year to evaluate the combination of company’s developmental immunotherapeutic and checkpoint inhibitors in NSCLC, metastatic melanoma and gastric cancer.
